EGFR decrease during antiviral C therapy with first generation protease inhibitors: A clinical significance?

Liver International

Volumn 35, Issue 1, 2015, Pages 71-78

  Loustaud Ratti, Véronique ^a,b   Rousseau, Annick ^a,c   Carrier, Paul ^a   Vong, Chanlina ^a   Chambaraud, Tristan ^a   Jacques, Jérémie ^a   Debette Gratien, Marilyne ^a   Sautereau, Denis ^a   Essig, Marie ^a,c  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UMR 1092   (France)

^c Univ Limoges   (France)

Author keywords

Boceprevir; Hepatitis C virus; Renal impairment; Telaprevir

Indexed keywords

BOCEPREVIR; CREATININE; ORGANIC CATION TRANSPORTER 2; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; PROLINE; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; DRUG DOSE REDUCTION; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PATIENT MONITORING; RETROSPECTIVE STUDY; SENESCENCE; SEX; TREATMENT DURATION; AGE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; KIDNEY; METABOLISM; SEX DIFFERENCE; STATISTICAL MODEL;

AGE FACTORS; ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; KIDNEY; LINEAR MODELS; MALE; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; SEX FACTORS;

EID: 84921022941     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12631     Document Type: Article

References (28)

1. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
2. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
4. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
5. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
6. Izzedine H, Launay-Vacher V, Bourry E, et al. Drug-induced glomerulopathies. Expert Opin Drug Saf 2006; 5: 95-106.
7. Morel-Maroger L, Sloper JC, Vinter J, Woodrow D, Gresser I. An ultrastructural study of the development of nephritis in mice treated with interferon in the neonatal period. Lab Investig J Tech Methods Pathol 1978; 39: 513-22.
8. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 1711-9.
9. Tempestilli M, D'Offizi G, Lionetti R, et al. Increased plasma concentration of Ribavirin as a result of renal dysfunction in HCV patients treated with telaprevir. Hepatology 2013; doi: 10.1002/hep.26978 [Epub ahead of print].
10. Karino T, Ozeki I, Hige S, et al. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepat 2014; 21: 341-7.
11. Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2014; 59: 46-8.
12. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-41.
13. Fukuda K, Imai Y, Hiramatsu N, et al. Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C. Hepatol Res 2014; doi: 10.1111/hepr.12229 [Epub ahead of print].
14. Loustaud-Ratti V, Carrier P, Vong C, Essig M. Reply to: renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2014; 59:2426.
15. Kunze A, Huwyler J, Camenisch G, Gutmann H. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol 2012; 84: 1096-102.
16. Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735-43.
17. Pariente A, Rémy A-J, Lesgourgues B, Hagège H, The APROVVIE group of the Association Nationale des Gastroentérologues des Hôpitaux Généraux (ANGH). Risk factors for severe anaemia during telaprevir-based triple therapy : is acquired renal dysfunction the missing link? Liver Int 2014; 34: e163-4.
18. Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 555-65.
19. Bruchfeld A, Lindahl K, Schvarcz R, Ståhle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24: 701-8.
20. Willson RA. Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C. J Clin Gastroenterol 2002; 35: 89-92.
21. Rettmar K, Kienast J, Van de Loo J. Minimal change glomerulonephritis with reversible proteinuria during interferon alpha 2a therapy for chronic myeloid leukemia. Am J Hematol 1995; 49: 355-6.
22. Ohta S, Yokoyama H, Wada T, et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney 1999; 33: 1040-8.
23. Selby P, Kohn J, Raymond J, Judson I, McElwain T. Nephrotic syndrome during treatment with interferon. Br Med J (Clin Res Ed) 1985; 290: 1180.
24. Traynor A, Kuzel T, Samuelson E, Kanwar Y. Minimal-change glomerulopathy and glomerular visceral epithelial hyperplasia associated with alpha-interferon therapy for cutaneous T-cell lymphoma. Nephron 1994; 67: 94-100.
25. Coroneos E, Petrusevska G, Varghese F, Truong LD. Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy. Am J Kidney Dis 1996; 28: 888-92.
26. Shah M, Jenis EH, Mookerjee BK, et al. Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. Cancer 1998; 83: 1938-46.
27. Jadoul M, Piessevaux H, Ferrant A, Cosyns JP, van Ypersele de Strihou C. Renal thrombotic microangiopathy in patients with chronic myelogenous leukaemia treated with interferon-alpha 2b. Nephrol Dial Transplant 1995; 10: 111-3.
28. Carrier P, Chambaraud T, Vong C, et al. Severe renal impairment during triple therapy with telaprevir. Clin Res Hepatol Gastroenterol 2014; doi: 10.1016/j.clinre.2013.12.005 [Epub ahead of print].